Why a Narrow Creative Slate Concentration Strategy Wins Q4
A creative slate concentration strategy beats broad testing in Q4, when network review slows and every new concept costs more time than it did in July.
A wide creative slate is the right default for most of the year, and most of this publication's advice reflects that. Testing many concepts against many audiences is how a team finds the hooks that outperform intuition, and concentrating too early usually means concentrating on the wrong thing. Q4 is the exception. A creative slate concentration strategy, built around fewer concepts pushed harder rather than more concepts tested wider, outperforms breadth for the specific six-to-eight week window most teams are entering now, and the reason has less to do with creative quality than with what happens to a media buying calendar once network review times start slowing.
Why breadth works most of the year and stops working now
Broad testing depends on a resource that gets scarcer heading into Q4: turnaround time. Nothing more complicated than that. A wide slate only pays off if underperforming concepts die quickly and winners scale while they are still fresh, and both of those actions need a network reviewing and approving new creative on a normal cadence. As UA Ledger set out in Q4 Creative Calendar Planning Before the Network Freeze, most networks slow creative review meaningfully once the holiday freeze approaches, which means a concept submitted in mid-November may not clear review until well into December, by which point the testing window that would have justified submitting it in the first place has closed. A wide slate built for a fast-review environment becomes a liability the moment the environment stops being fast.
What concentration actually means
Concentration does not mean fewer creative assets in absolute terms. It means fewer distinct concepts, each carrying more variants, more formats, more length cuts than a team would normally justify for an unproven idea. The logic: a concept that already carries Q3 evidence behind it, or evidence from an earlier cohort, is a safer bet to over-invest in during a slow-review window than a new idea that has not yet earned that evidence and would need the review cycles Q4 does not reliably offer.
This is the same logic behind the retirement discipline UA Ledger argued for in Creative Variant Retirement Rules for a Live Portfolio, applied in reverse. Instead of asking when to cut a fading winner, the Q4 question is which proven winners deserve the disproportionate share of a shrinking testing budget before the freeze removes the option to decide.
The concentration math
Consider a hypothetical portfolio that ran twelve active concepts through Q3: four clear performers, five holding roughly at benchmark, three underperforming enough to carry a retirement flag already. A team following the normal broad-testing cadence into Q4 replaces the three underperformers with three new concepts and keeps testing all fourteen. A concentration team does something else. It retires the three underperformers without replacement, folds the five at-benchmark concepts down to the two that show the clearest signal of scaling further, then puts the freed testing budget, roughly 40% of total creative spend in this hypothetical, behind deeper format variants and deeper audience variants of the four proven winners. The second team enters the freeze with six concepts instead of fourteen. Each one carries more submitted variants already cleared and live, which is exactly the inventory that survives a slow review period intact.
Where breadth still wins, even in Q4
This is not an argument for abandoning testing discipline. A studio launching a new title in Q4, or entering a market it has no creative history in, still needs breadth, because it has no proven winners to concentrate around and concentrating on an unproven concept just means betting the freeze on a guess. The concentration argument applies to a live, mature portfolio with an established Q3 track record, which describes most of the accounts running significant Q4 holiday budget. New launches and market entries keep testing wide while everyone else narrows.
Creative slate concentration strategy: a decision checklist
A team unsure whether its own portfolio qualifies for concentration this quarter can run four checks rather than defaulting to habit:
- Does the portfolio have at least three concepts with a full quarter of performance data behind them. Without that history, there is nothing proven to concentrate around, and the portfolio should keep testing broadly regardless of the calendar.
- Is the account a live, mature title rather than a Q4 launch or new market entry. New launches lack the track record concentration depends on and should stay in discovery mode through the freeze.
- Has the team confirmed with its own network contacts how much review times have actually slowed this year, rather than assuming last year's slowdown repeats exactly. Review slowdowns vary year to year and network to network, and the concentration decision should be sized to the actual slowdown observed, not a generic assumption.
- Has a specific share of the freed testing budget been assigned to the surviving concepts' variants, rather than simply reduced overall. Concentration that just cuts spend without reallocating it toward deeper variant coverage forfeits the benefit this strategy is meant to produce.
The trade-off worth naming
Concentration trades discovery for reliability. A team that narrows its slate in October will find fewer new winners over the following two months than a team that kept testing broadly, and that is a real cost rather than a hidden win. The bet is that the discovery a wide slate would have produced during the freeze window is worth less than the certainty of having proven creative already cleared and live when review times sit at their slowest. For most mature Q4 accounts, make that trade deliberately, in October, rather than by accident in December when the freeze has already made the decision for the team that never chose to narrow.
What to watch next
Watch how quickly review times recover once the freeze lifts in January, since a slower-than-usual recovery would argue for holding the concentrated slate longer into Q1 rather than reopening broad testing immediately. And watch whether any network publishes its own freeze-period review benchmarks. A network confirming its own slowdown publicly would give teams a firmer basis for a future concentration decision than the mostly informal signals available this year.
